OBJECTIVES: Discrete event simulation (DES) is a tool that allows for the organizational domain to be quantified within health technology assessment (HTA). This research demonstrates how DES can be used to model improved access to care for children with medically refractory epilepsy (MRE).
OBJECTIVES:
To calculate and compare the incremental cost-utility ratios for standard antiepileptic drug (AED) therapy with and without adjunctive lacosamide in patients with uncontrolled partial-onset seizures in Turkey. METHODS: A model simulated the treatment pathway of a hypothetical cohort of 1000 patients over two years from the third-party payer perspective in Turkey in 2012. A decision tree was split into four phases of six months during which patients could become seizure free, experience a response to treatment (responder defined as ≥50% reduction in seizures), or withdraw due to nonresponse. The standard therapy arm included five adjunctive therapies: carbamazepine, lamotrigine, levetiracetam, topiramate, and valproate. The likelihood of being in a particular health state was estimated from clinical trial data. The cost of general practitioner visits, specialist visits, hospitalizations and emergency department visits were included. Costs and utility values attached to various health states were taken from the published literature. RESULTS: Compared with the standard therapy arm, lacosamide adjunctive therapy was associated with 6,730 seizures avoided and a gain of 38 quality adjusted lifeyears (QALYs). Treatment with lacosamide was associated with an additional cost of Turkish Lira (TRY) 205 per seizure avoided and TRY 36,392 per QALY gained versus standard therapy without LCM over two years. Results calculated for 6-, 12-and 18-month follow-up showed respective incremental cost-utility ratios of TRY 38,146, TRY 37,629 and TRY 37,556 and cost per seizure avoided of TRY 504, TRY 246 and TRY 219. Sensitivity analysis indicates the base case findings are robust, however the model was most sensitive to changes in the utility weights. CONCLUSIONS: Lacosamide may be a cost-effective adjunctive treatment for patients with uncontrolled partial-onset epilepsy in Turkey. UCBfunded
PND49 CLINICAL AND ECONOMIC IMPACT OF FIVE-YEAR ADHERENCE TO DISEASE-MODIFYING THERAPIES IN A COMMERCIALLY INSURED MULTIPLE SCLEROSIS POPULATION
Bunz TJ, Xu C, Regine ML, Couto JE Cigna, Bloomfield, CT, USA OBJECTIVES: Several published studies have reported the clinical and economic impact of adherence to disease-modifying therapies (DMTs) for multiple sclerosis (MS), although none have examined the impact of adherence exclusively in patients continuously enrolled for five years. The objectives of this study were to understand some of the clinical and economic outcomes associated with longterm adherence/non-adherence to DMTs in MS patients. METHODS: Patients who had a medical or pharmacy claim for a DMT between January 1, 2005 to December 31, 2005 and who were continuously enrolled until December 31, 2011 were included in this retrospective cohort study. A total of 664 patients met eligibility criteria, and were defined as adherent if they had a medication possession ratio (MPR) of greater than 80% in all five years. Propensity Score Bin-Bootstrapping method was used to control for the variation between the adherent and non-adherent groups. Variables used to calculate propensity scores were age, gender, comorbidities and severity of disease. RESULTS: Compared with the non-adherent group, the adherent group had significantly fewer inpatient relapses per year (0.339 vs. 0.215, p<0.01) and had lower annual unadjusted medical costs. The non-adherent group had significantly higher (p<0.05) adjusted annual medical costs than their matched adherent counterparts in all 5 years of the study, except for year 1. From year 1 to year 5, adjusted medical costs increased 235% in the non-adherent group compared to 93% in the adherent group. CONCLUSIONS: MS patients with consistently high medication adherence to DMTs over a 5 year period had lower rates of inpatient relapse and lower total medical costs than their non-adherent counterparts.
Given the high cost of DMTs to both payers and patients, it is imperative to support and encourage high adherence when using these agents in order to get the most value out of the investment in DMTs.
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COMPARISON OF PATIENT CHARACTERISTICS AND HEALTH CARE UTILIZATION IN EPILEPSY PATIENTS ADDING ADJUNCTIVE LACOSAMIDE TO SODIUM CHANNEL BLOCKERS VERSUS NON-SODIUM CHANNEL BLOCKERS
Burke JP 1 , Durgin T 2 , Zackheim J 2 , Simontacchi K 2 , Gomez-Rey G 1 1 OptumInsight, Eden Prairie, MN, USA, 2 UCB Pharma, Smyrna, GA, USA OBJECTIVES: Lacosamide is an antiepileptic drug (AED) that enhances sodium channel slow inactivation and is approved for adjunctive treatment of partialonset seizures in adults. There have been few studies examining patient characteristics in patients receiving sodium channel blocking (SCB) versus nonsodium channel blocking (nSCB) AEDs in addition to lacosamide. The objective of this study was to compare patient characteristics and health care utilization in nSCB and SCB patients prior to adding lacosamide in a real-world setting. METHODS: This was a retrospective database analysis using eligibility, medical and pharmacy claims data from a large US health care organization. For inclusion, patients had evidence of epilepsy, were continuously enrolled for 6 months prior to (pre-index) and after (post-index) the 1 st pharmacy claim for lacosamide (index date), and were receiving at least one other AED (SCB or nSCB) for 60 days prior to the index date. If patients were taking ≥1 SCB, they were assigned to the SCB group. RESULTS: A total of 720 patients (382 SCB, 338 nSCB) met study criteria. Mean age was 35.9 years; 55.7% were female. A total of 62.6% of SCB and 30.2% of nSCB patients (p<0.001) were receiving ≥2 AEDs prior to adding lacosamide. nSCB patients had higher mean pre-index Quan-Charlson Comorbidity (CCI) scores [0.94(SD 1.48) versus 0.49(1.07); p<0.001] and epilepsyattributable events [0.56(0.99) versus 0.39(0.84); p=0.015] compared with SCB patients. Pre-index health care utilization, including inpatient [0.44(0.85) versus 0.29(0.68); p=0.006], ER [0.91(2.11) versus 0.60(1.13); p=0.015], physician office [10.06(9.86) versus 8.42(9.34); p=0.022] and outpatient visits [5.78(7.95) versus 4.09(5.78); p=0.001], was higher in nSCB patients compared to SCB patients. CONCLUSIONS: Prior to the addition of lacosamide, nSCB patients had greater comorbidities, epilepsy-attributable events, and overall health care utilization compared to patients using SCB. These findings suggest that nSCB patients had a more severe clinical profile compared to SCB patients prior to adding lacosamide. Aggarwal S, Topaloglu H Novel Health Strategies, Bethesda, MD, USA OBJECTIVES: During 2007 -2011 was the only category that experienced triple digit growth in sales, leading to a doubling of their sales from $3.4 billion in 2007, to $7 billion in 2011. This has led to change in payer coverage and utilization of branded MS products. This study was undertaken to understand current trends in sales, access, and utilization management for MS products in the United States. METHODS: Sales data for MS branded products was analyzed using IMS Health 2007-2011 data. Access and utilization management trends were analyzed using preferred drug lists and coverage policies of top U.S. health plans. To understand new trends in coverage of MS products, primary discussions were conducted with pharmacy and medical directors to understand new trends in coverage of MS products. RESULTS: More than half (approximately 59%) of the branded MS products were covered by health plans as non-preferred products or at Tier 3/4. A significant majority (84%) of these products were covered with prior authorization or pre-certification criteria. Quantity limits were used by 34% of the plans. Use of step therapy or progression prescription is not currently common and was found in only 5% of the plans. In this sample (n=37), only one plan (<5%) had formulary exclusion for an MS product. Payer designated specialty pharmacies are increasingly being used by various health plans. Compared to 2007, payer coverage of MS products shows significant increase in use of PA (40% in 2007 PA (40% in , vs. 84% in 2012 . Payers express high concern for the rapidly growing MS category and report use of more utilization management approaches to control spending. CONCLUSIONS: MS products are facing more aggressive utilization management. Patient access for new MS therapies could be limited due to non-preferred status, high co-pay, or strict PA criteria.
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